Janux Therapeutics, Inc. has announced a proposed underwritten public offering to sell $175.0 million of its common stock. This capital raise is expected to fund ongoing operations and development, but will result in share dilution for existing shareholders.
Janux Therapeutics Announces Proposed $175 Million Public Stock Offering
Public OfferingBiotechnologyCorporate FinanceShare DilutionCapital Raise
